AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor-positive advanced breast cancer are limited.

Paper PDF

This PDF hasn't been uploaded yet.

Do not upload any copyrighted content to the site, only open-access content.